CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Short Interest Up 87.7% in August

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) saw a large growth in short interest in the month of August. As of August 31st, there was short interest totalling 202,500 shares, a growth of 87.7% from the August 15th total of 107,900 shares. Based on an average daily trading volume, of 5,550,000 shares, the short-interest ratio is presently 0.0 days.

CNS Pharmaceuticals Price Performance

Shares of NASDAQ:CNSP remained flat at $0.15 during trading on Friday. 1,391,780 shares of the stock were exchanged, compared to its average volume of 2,074,843. The business’s 50-day simple moving average is $0.50 and its two-hundred day simple moving average is $7.38. CNS Pharmaceuticals has a fifty-two week low of $0.10 and a fifty-two week high of $137.50. The company has a market capitalization of $213,852.60, a price-to-earnings ratio of 0.00 and a beta of 2.58.

CNS Pharmaceuticals (NASDAQ:CNSP) last issued its earnings results on Wednesday, August 14th. The company reported ($6.72) earnings per share for the quarter.

Analyst Upgrades and Downgrades

Separately, Maxim Group raised shares of CNS Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 price objective for the company in a research note on Tuesday.

Institutional Trading of CNS Pharmaceuticals

An institutional investor recently raised its position in CNS Pharmaceuticals stock. Virtu Financial LLC grew its holdings in CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) by 616.6% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 94,246 shares of the company’s stock after purchasing an additional 81,094 shares during the quarter. Virtu Financial LLC owned approximately 0.80% of CNS Pharmaceuticals worth $34,000 at the end of the most recent reporting period. 14.02% of the stock is owned by institutional investors.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.